Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
about
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive ReviewGlucocorticoid-induced osteoporosisOsteoporosis and fractures in liver disease: relevance, pathogenesis and therapeutic implicationsOsteoimmunology and the influence of pro-inflammatory cytokines on osteoclastsMultiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationshipBiologic therapies and bone loss in rheumatoid arthritis.Bone remodelling markers in rheumatoid arthritis.Role of endogenous and exogenous female sex hormones in arthritis and osteoporosis development in B10.Q-ncf1*/* mice with collagen-induced chronic arthritis.Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment.Bone damage in rheumatoid arthritis: mechanistic insights and approaches to preventionBone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesDifferential effects of locally and systemically administered soluble glycoprotein 130 on pain and inflammation in experimental arthritis.Cytokine-mediated bone destruction in rheumatoid arthritis.Vitamin D deficiency in chronic liver disease.Peroxiredoxin II negatively regulates lipopolysaccharide-induced osteoclast formation and bone loss via JNK and STAT3Macrophage infiltration predicts a poor prognosis for human ewing sarcoma.Blockade of IL-36 receptor signaling does not prevent from TNF-induced arthritis.Positive regulators of osteoclastogenesis and bone resorption in rheumatoid arthritisA Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis.Interleukin-6-dependent influence of nociceptive sensory neurons on antigen-induced arthritis.Gene Expression Profiling of IL-17A-Treated Synovial Fibroblasts from the Human Temporomandibular JointUnderstanding and targeting osteoclastic activity in prostate cancer bone metastases.Body composition, soluble markers of inflammation, and bone mineral density in antiretroviral therapy-naive HIV-1-infected individualsABL kinases promote breast cancer osteolytic metastasis by modulating tumor-bone interactions through TAZ and STAT5 signaling.Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5Bioinformatics and Microarray Analysis of miRNAs in Aged Female Mice Model Implied New Molecular Mechanisms for Impaired Fracture Healing.High fat diet increases melanoma cell growth in the bone marrow by inducing osteopontin and interleukin 6Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITYRecent advances in neutralizing the IL-6 pathway in arthritis.Association of periodontitis with rheumatoid arthritis and atherosclerosis: Novel paradigms in etiopathogeneses and management?Essential Oils from Ugandan Medicinal Plants: In Vitro Cytotoxicity and Effects on IL-1β-Induced Proinflammatory Mediators by Human Gingival Fibroblasts.Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate.Osteoporosis in inflammatory joint diseases.Effects of inflammatory and anti-inflammatory cytokines on the bone.Bone, inflammation, and inflammatory bowel disease.Mechanisms of tissue damage in arthritis.Alternative pathways of osteoclastogenesis in inflammatory arthritis.Biocompatibility of defect-related luminescent nanostructured and microstructured hydroxyapatite.Nociceptive neurons detect cytokines in arthritisOsteoblast-secreted factors enhance the expression of dysadherin and CCL2-dependent migration of renal carcinoma cells.
P2860
Q26774874-5C48884F-8CD8-4925-87D8-EE43824DCC3EQ26778272-A78B9E43-793E-48DC-A965-E15D16336B15Q26824690-F3EC48B2-AFC5-40C4-AF3A-61F5B033AA07Q26828486-EEE7CD15-3812-401F-8583-6F4E693094FFQ28066958-EC3C8EB1-5E40-49BB-B2CE-346B70B0E7CCQ30243911-BEF6993C-E148-4712-8287-9742503297D8Q33563068-99B5A73E-2120-40CB-B25E-4814A4FA3447Q33772317-D7296976-F87F-4E42-93BF-875A1D99FA2FQ33896725-E8B96CC5-CAA4-4601-AEE8-10CDE6E0496EQ34001621-5C16680A-FA0C-4EDC-898D-0CE450E72F0DQ34132305-723A34B5-736F-44AC-9437-82A2C48990C8Q34152981-94740E7E-653A-4C71-B326-A9AF0DD9C969Q34252489-DF0D6E1C-9BD9-413C-86D4-22158ABE6D73Q34728285-10CFDFF9-8549-473A-B956-7DC170849C42Q34729815-2131CBD8-696D-48BD-8DBA-E0E22A4E1A41Q35168030-56102F47-7F52-4A1A-95D3-4D171364C2C6Q35222786-D053F104-6CFB-4576-A167-ADF566EA21E8Q35617594-2DA559FD-9315-4A18-864F-96FFC466908AQ35913704-6684D086-41D2-4C4A-ADDD-2402EC492523Q36304006-2034CB9A-9DC1-4EDD-AA70-1ABF63B1780AQ36453925-49ED4DC3-26B1-41BF-9760-8913F01F793AQ36759374-ADC9A844-E95E-474E-A86E-5DD2279C8155Q36958022-8D5C08F3-AA6D-4C99-A37D-CA94A0C70FF8Q37189265-E53E3FC8-E4DC-4894-B62D-EF02E232B45CQ37195704-A58BE909-5D53-4558-B933-66B3ABC6E1B5Q37209989-1D65C60B-C40D-4A58-A0AA-B4F7585694C2Q37295749-CE4BA34A-3D00-4593-83C9-3C8C50207A1AQ37315782-CFC0C68A-2E7D-4569-B8E6-F6CDD283CCF9Q37358099-6C1A6AB4-7A13-482A-9EB0-9720EBFFB43FQ37358225-BA7316E7-2E8D-4D6D-8684-EF28F5334F2FQ37363671-328EC5FD-59D2-4CC2-B0C7-C3ABC5FB1B4AQ37690607-A142FDC4-01E7-40EE-B767-EE4DDA5EEAA3Q37765505-03186B60-1E29-4323-9E55-5A26E04BDFB3Q37880163-E1220425-B1A0-41FE-B197-2C929D7C2E13Q37936285-19846567-41F9-48C6-9D3C-813040A33E4AQ38248430-33364DB3-66A2-4025-BBEE-E025892740B3Q38271156-6C1069FE-54B7-4898-8241-B524C703A1ECQ38303536-AFE2EF9F-98F6-4D54-81FC-DBF1F3B4D5AFQ38326591-6F23D2FD-782A-4453-A403-9389C54E3E45Q38337275-142783CC-8B11-4BC8-8FDD-F77618559B46
P2860
Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@en
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@nl
type
label
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@en
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@nl
prefLabel
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@en
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@nl
P2093
P2860
P50
P356
P1476
Inhibition of interleukin-6 re ...... ormation in vitro and in vivo.
@en
P2093
Christina Böhm
Jochen Zwerina
Roland Axmann
P2860
P304
P356
10.1002/ART.24781
P577
2009-09-01T00:00:00Z